Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China’s National Reimbursement Drug List

December 14, 2023

https://www.prnewswire.com/news-releases/antengene-announces-inclusion-of-xpovio-selinexor-in-2023-chinas-national-reimbursement-drug-list-302014837.html

SHANGHAI and HONG KONG, Dec. 13, 2023 /PRNewswire/ — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that XPOVIO® (selinexor) has been added to the National Reimbursement Drug List (2023 Version) (“NRDL”) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) whose disease is refractory to at least one proteasome inhibitors (PIs), one immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody (mAb). The updated NRDL will officially take effect on January 1, 2024.

Read more at prnewswire.com

Related news for (KPTI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.